Pet Cancer Therapeutics Market, By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Combination Therapy), By Pet Type (Dog, Cat and Others), By Mode of Administration (Oral, Topical, Intravenous), By Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer and Others) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2034

Pet Cancer Therapeutics Market Size was valued at USD 474.36 million in 2024 and is projected to grow at a CAGR of 8.2% to reach USD 975.49 million by 2034.

Unlike humans, many other species of pet such as dogs and cats are susceptible to the same types of cancer as humans. Canine cancer accounts to register higher number of deaths in dogs of 10 years of age and older. However, half of all cancer in dogs is treatable if it is arrested in its early stages. The most common types of cancer found in pets are lymphoma, mast cell tumors, hemangiosarcoma, osteosarcoma, bladder cancer, brain tumor, mammary carcinoma, malignant histiocytosis, mouth and nose cancer, squamous cell carcinomas, melanoma, among others. When it comes to treating with cancer, chemotherapy, radiation and surgery are mostly recommended treatment regime either alone or in combination. 

Growing incidence and prevalence rate of pet cancers, increasing research and development (R&D) expenditures in the management of pet cancers will augment the growth of pet cancer therapeutics market. Furthermore, various key players to extensively offer cancer drugs in the treatment of pet cancer will further help to drive pet cancer therapeutics market, during the forecast period. 

For instance, in January 2017, the U.S. Food and Drug Administration (FDA), grants conditional approval of Tanovea-CA1 (rabacfosadine for injection) for the treatment of canine lymphoma. The conditional approval allowed VetDC, Inc., a veterinary cancer therapeutic company and manufacturer of Tanovea-CA1, to legally sell his new animal drug in the market, prior to get an approval. Further, in April 2017, VetDC commercially available theTanovea-CA1in the U.S.for the treatment of lymphoma in dogs.

The pet cancer therapeutics market has been segmented on the basis of therapy type, pet type, mode of administration, application and region.

The therapy type segment includes chemotherapy, targeted therapy, immunotherapy, and combination therapy.  Further, Pet type segmented into dog, cat and others. 

On the basis of mode of administration, the pet cancer therapeutics market segmented into oral, topical and intravenous. 

On the basis of application, the pet cancer therapeutics segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer & others

Regional Insights:

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the pet cancer therapeutics market, owing to increase in incidence and prevalence of pet cancer cases, growing number of pet cancer drugs approvals in these region, and growing research and development (R&D) expenditures in these region.

Key players operating in the pet cancer therapeutics market include Zoetis, VetDC, Inc., BoehingerIngelheim International GmbH, Zenoaq, Aratana Therapeutics, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Oasmia Pharmaceuticals AB, and Rhizen Pharmaceuticals SA.